X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with J.B.Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs J.B.CHEMICALS - Comparison Results

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA J.B.CHEMICALS SHASUN PHARMA/
J.B.CHEMICALS
 
P/E (TTM) x 123.9 14.7 842.8% View Chart
P/BV x 8.5 2.3 367.0% View Chart
Dividend Yield % 0.2 0.2 139.9%  

Financials

 SHASUN PHARMA   J.B.CHEMICALS
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
J.B.CHEMICALS
Mar-16
SHASUN PHARMA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs94318 29.6%   
Low Rs46200 22.9%   
Sales per share (Unadj.) Rs214.2148.0 144.7%  
Earnings per share (Unadj.) Rs5.319.1 28.0%  
Cash flow per share (Unadj.) Rs15.823.9 66.1%  
Dividends per share (Unadj.) Rs1.000.50 200.0%  
Dividend yield (eoy) %1.40.2 740.5%  
Book value per share (Unadj.) Rs53.3128.9 41.4%  
Shares outstanding (eoy) m56.6284.82 66.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.7 18.7%   
Avg P/E ratio x13.113.6 96.6%  
P/CF ratio (eoy) x4.410.8 40.9%  
Price / Book Value ratio x1.32.0 65.3%  
Dividend payout %18.72.6 715.3%   
Avg Mkt Cap Rs m3,95821,951 18.0%   
No. of employees `000NA2.7 0.0%   
Total wages/salary Rs m2,1641,841 117.5%   
Avg. sales/employee Rs ThNM4,590.9-  
Avg. wages/employee Rs ThNM673.4-  
Avg. net profit/employee Rs ThNM592.1-  
INCOME DATA
Net Sales Rs m12,12712,551 96.6%  
Other income Rs m229542 42.3%   
Total revenues Rs m12,35613,093 94.4%   
Gross profit Rs m1,0092,055 49.1%  
Depreciation Rs m594412 143.9%   
Interest Rs m41596 433.8%   
Profit before tax Rs m2302,088 11.0%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73469 -15.5%   
Profit after tax Rs m3021,619 18.7%  
Gross profit margin %8.316.4 50.8%  
Effective tax rate %-31.722.5 -140.9%   
Net profit margin %2.512.9 19.3%  
BALANCE SHEET DATA
Current assets Rs m6,8847,778 88.5%   
Current liabilities Rs m8,4564,358 194.0%   
Net working cap to sales %-13.027.2 -47.6%  
Current ratio x0.81.8 45.6%  
Inventory Days Days6255 112.7%  
Debtors Days Days10880 134.4%  
Net fixed assets Rs m4,9705,713 87.0%   
Share capital Rs m113170 66.8%   
"Free" reserves Rs m2,87510,547 27.3%   
Net worth Rs m3,02010,937 27.6%   
Long term debt Rs m1,8170-   
Total assets Rs m13,34715,574 85.7%  
Interest coverage x1.622.8 6.8%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.90.8 112.7%   
Return on assets %5.411.0 48.8%  
Return on equity %10.014.8 67.6%  
Return on capital %13.320.0 66.7%  
Exports to sales %46.448.7 95.1%   
Imports to sales %14.27.1 201.2%   
Exports (fob) Rs m5,6226,115 91.9%   
Imports (cif) Rs m1,728889 194.4%   
Fx inflow Rs m5,8436,169 94.7%   
Fx outflow Rs m2,1731,285 169.1%   
Net fx Rs m3,6694,884 75.1%   
CASH FLOW
From Operations Rs m3981,397 28.5%  
From Investments Rs m-1,635-320 510.5%  
From Financial Activity Rs m1,309-1,196 -109.4%  
Net Cashflow Rs m71-102 -69.6%  

Share Holding

Indian Promoters % 39.2 55.4 70.8%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 3.6 3.4 106.2%  
FIIs % 17.6 3.9 451.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 37.0 107.0%  
Shareholders   20,750 30,437 68.2%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH LTD  ABBOTT INDIA  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS